Introduction: Hypertension is a leading cause of cardiovascular morbidity and mortality, and
uncontrolled hypertension remains common despite the availability of several classes of …

Cardiovascular-related morbidity and mortality is linked to hypertension with proportional
gains in cardiovascular risk factor reduction with the lowering of blood pressure. Clinical trial …

High blood pressure is the leading risk factor for death and disability worldwide, and the
prevalence is increasing. Effective treatment decreases the risk of adverse events in …

J Clin Hypertens (Greenwich). 2012; 14: 821–827.© 2012 Wiley Periodicals, Inc.
Combination antihypertensive therapies are recommended to attain blood pressure (BP) …

Objectives: To evaluate the clinic and ambulatory blood pressure (BP)-lowering efficacy and
safety of an aliskiren/amlodipine/hydrochlorothiazide (HCT) triple combination compared …

A majority of hypertensive patients need more than one antihypertensive drug to control their
blood pressure. For this reason, most guidelines have introduced the possibility of …

Many patients with hypertension will require multiple antihypertensive drugs to achieve
blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of …

Most patients with hypertension need more than one drug to achieve blood pressure (BP)
control. This randomized, double-blind, multifactorial study evaluated whether combinations …

Hypertension is a major risk factor for cardiovascular morbidity and mortality and currently
has been estimated at 30% of the US population. Of these, only 36.8% have their blood …

Abstract▲ Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new
class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic …